Angiotensin Receptor Neprilysin Inhibitors—2019 Update
- 9 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 34 (5), 707-722
- https://doi.org/10.1007/s10557-020-07015-8
Abstract
An abundance of new data regarding the use of the novel drug compound sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the initial publication of the PARADIGM-HF study in 2014. This review summarises the most recent evidence (2019 and onwards) of sacubitril/valsartan in CHF patients as well as provides a critical appraisal of these data. New data are grouped in categories such as real-world data, randomised controlled trials, surrogate end-points, cost-effectiveness, use of sacubitril/valsartan as an anti-hypertensive treatment, effect on diuretic dosing and implementation of this novel compound in other populations. This review of recent literature identified important messages such as early initiation during index hospitalisation or immediately post-discharge, barriers against implementation of this novel treatment modality, analytical issues regarding measuring natriuretic peptides in patients under treatment and extrapolated use of sacubitril/valsartan in other than PARADIGM-HF populations. This update may serve as a very helpful evidence-based resource for practising clinicians, future research planning and health-related policy makers.Keywords
This publication has 117 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart FailureThe New England Journal of Medicine, 2019
- Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot StudyRevista Española de Cardiología (English Edition), 2019
- Effects of sacubitril/valsartan on functional status and exercise capacity in real-world patientsActa Cardiologica, 2018
- The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case seriesJournal of Oncology Pharmacy Practice, 2018
- Impact of sacubitril/valsartan on heart failure admissions: insights from real-world patient prescriptionsActa Cardiologica, 2018
- In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalizationHerz, 2018
- Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndromeActa Cardiologica, 2018
- Cognitive performance of patients with chronic heart failure on sacubitril/valsartanHerz, 2018
- PARADIGM‐HF Trial: Secondary Analyses Address Unanswered QuestionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Sacubitril/valsartan for heart failure with reduced left ventricular ejection fractionHerz, 2018